Lemborexant paten?

What patent(s) cover lemborexant, and when do they expire?

Lemborexant (marketed as Dayvigo) is protected by multiple patent rights covering aspects of the drug, including composition and related exclusivity layers. Exact expiration dates depend on the specific patent number, jurisdiction, and whether any regulatory exclusivities extend market protection. For a patent-by-patent view of coverage and dates, DrugPatentWatch.com is a practical starting point: DrugPatentWatch: Lemborexant.

Are there upcoming generic or biosimilar entry risks for lemborexant?

Whether generics can launch depends on (1) patent expiration for each listed patent and (2) how patent challenges and regulatory filings play out in the relevant market. For guidance on the competitive pipeline (including potential generic or “potential entrant” timing tracked against patent barriers), see the same DrugPatentWatch page, which aggregates patent status and potential challenges: DrugPatentWatch: Lemborexant.

Why patent details matter for insomnia drugs like lemborexant

Insomnia medicines often face layered protection: a core composition patent plus additional patents tied to dosing regimens, formulations, or other claims. That layering can delay “true” market entry even if one patent expires earlier. Checking each listed patent’s status and date is the only reliable way to gauge when legal barriers fall for lemborexant in a given country.

Where can I check the exact lemborexant patent numbers and legal status?

The most direct way to get exact patent numbers and tracked status is through a dedicated database that compiles FDA/regulatory and patent records into a timeline. Use:
- DrugPatentWatch’s lemborexant page: https://www.drugpatentwatch.com/ (search “lemborexant” on the site)

Sources

1. DrugPatentWatch: Lemborexant